Structure Therapeutics (GPCR) vs Xencor (XNCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Xencor (XNCR) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 88.6% versus a loss of 16.4%. Xencor is the larger company by market cap ($1.83 billion vs $1.82 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | XNCR |
|---|---|---|
| Share price | $25.54 | $24.63 |
| Market cap | $1.82B | $1.83B |
| 1-day change | -0.51% | +0.53% |
| YTD return | -63.28% | +60.88% |
| 1-year return | -16.40% | +88.59% |
| 5-year return | — | -35.98% |
| EPS (TTM) | $-3.03 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $125.58M |
| Revenue growth (YoY) | — | +13.65% |
| Net income (latest FY) | $-141.20M | $-91.92M |
| Operating margin | — | -141.35% |
| Net margin | — | -73.20% |
| 52-week high | $94.90 | $30.61 |
| 52-week low | $25.09 | $10.38 |
| Distance from 52-week high | -73.09% | -19.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +314.17% | +27.57% |
| Average volume | 968.62K | 1.32M |
| Shares outstanding | 71.31M | 74.35M |
| Employees | 281 | 260 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- XNCR has outperformed GPCR by 105.0 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About Xencor
XNCR stock →Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 260 employees
GPCR vs XNCR FAQ
Which is bigger, Structure Therapeutics or Xencor?
Xencor (XNCR) is larger, with a market capitalization of $1.83B compared with $1.82B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GPCR or XNCR?
XNCR returned +88.59% over the past 12 months, compared with -16.40% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Xencor in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.